Streetbeat News

Stock Prices

MPW

Medical Properties Trust (NYSE:MPW) has received mixed analyst ratings over the past three months, with a recent shift towards a more bearish outlook. The average 12-month price target is now $4.75, a significant decrease from the previous $8.33. Analysts from RBC Capital, Deutsche Bank, Mizuho, and JP Morgan have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline, market capitalization, and financial performance despite its strong net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

CMI

Evercore ISI Group has maintained its In-Line rating for Cummins (NYSE:CMI) and increased its price target from $231.00 to $244.00. Despite a current trading price of $263.85, which is down 0.99% over the last 24 hours, the new target suggests a potential decline of 7.52%. Cummins is a leading manufacturer of diesel engines and powertrain components, facing competition from heavy-duty truck manufacturers and regulatory challenges.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

HRL

Hormel Foods (NYSE:HRL) has seen a 6.25% increase in short interest since its last report, with 12.97 million shares sold short, representing 2.38% of its float. It would take about 4.38 days to cover all short positions. This rise in short interest could indicate a more bearish market sentiment towards HRL, although it has less short interest compared to its peers' average of 5.30%.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

RS

BMO Capital has maintained its Outperform rating for Reliance (NYSE:RS) and increased its price target from $295.00 to $355.00. Despite a slight decrease in share price over the last 24 hours, the new target suggests a potential 9.1% increase.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:00 pm

KBR

KBR, Inc. (NYSE:KBR) reported Q4 adjusted earnings per share of 69 cents, matching expectations, but missed quarterly sales estimates with $1.73 billion versus the expected $1.787 billion. Year-over-year, revenue rose 8%, and adjusted EBITDA increased by 20%. The company's backlog increased by 10% to $21.7 billion. KBR raised its quarterly dividend by 11% to $0.15 per share and replenished its share repurchase authorization to $500 million. For FY24, KBR forecasts revenue between $7.4 billion and $7.7 billion, slightly below the $7.73 billion estimate, with adjusted EPS of $3.10-$3.30, against an estimate of $3.26. KBR shares rose 4.33% to $57.69.

Portfolio Pulse from Nabaparna Bhattacharya

February 20, 2024 | 4:56 pm

AXSM

Axsome Therapeutics' stock price declined following the announcement of worse-than-expected Q4 earnings per share (EPS) results.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 4:55 pm

BAC

C

GS

JPM

KRE

MS

NYCB

SFBS

VLY

WFC

XLF

Rising delinquencies in the commercial real estate sector are causing concerns for major banks like JPMorgan Chase, Bank of America, Wells Fargo, Citigroup, Goldman Sachs, and Morgan Stanley, as bad loans begin to exceed loss reserves. The Financial Times reports a significant drop in average reserves against delinquent debt, with a nearly tripled delinquent debt reaching $9.3 billion. The banking sector's scrutiny by regulators increases as delinquent loans tied to commercial properties more than double to $24.3 billion. The Financials SPDR Select Sector Fund and the SPDR S&P 500 Regional Banking ETF saw declines, with New York Community Bancorp, ServisFirst Bancshares, and Valley National Bancorp experiencing notable stock drops.

Portfolio Pulse from Piero Cingari

February 20, 2024 | 4:53 pm

IOVA

Iovance Biotherapeutics' stock is trading higher following the FDA's accelerated approval of AMTAGVI for advanced melanoma.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 4:52 pm

BHP

BHP Group shares are trading lower following the release of their 1H earnings report.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 4:50 pm

FLR

Fluor Corp (NYSE:FLR) reported a Q4 fiscal 2023 revenue of $3.82 billion, missing the consensus of $4.11 billion, with a net loss of $21 million compared to net earnings of $9 million a year ago. Despite this, adjusted EPS improved to $0.68, beating the consensus of $0.57. The company saw a total new awards of $7.6 billion, up from $4.6 billion a year ago, and expects improved cash flow conversion in 2024 with adjusted EBITDA of $600 million to $700 million and adjusted EPS of $2.50 to $3.00. FLR shares traded lower by 10.46% at $37.73.

Portfolio Pulse from Akanksha Bakshi

February 20, 2024 | 4:47 pm